A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer

Tsunehiro Takahashi, Yoshiro Saikawa, Masashi Yoshida, Yuukou Kitagawa, Yoshihide Otani, Tetsuro Kubota, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The surgical outcome for advanced gastric cancer, even following curative surgery, is associated with a poor prognosis. A pilot study in advanced gastric cancer patients was carried out using pre-operative chemotherapy with S-1 and low-dose cisplatin (CDDP) (TSLD). Patients and Methods: Twenty-one patients with stage IV gastric cancer were treated with TSLD as the initial treatment, after informed consent had been obtained. Surgery was performed when curative resection was deemed feasible in selected patients who showed improvement in their tumors. Other regimens including CPT-11 or taxanes were utilized as second-line chemotherapy when the tumor showed no change or progressive disease following TSLD therapy. Results: No patient had a complete response, while 11 had partial responses following TSLD therapy, yielding an overall response rate of 52.4%. Fifteen out of 21 (71.4%) underwent surgery following TSLD therapy, while curative surgery determined by histological investigation was performed in 10 out of 15 (47.6%) patients. No grade 4 toxicities or treatment-related deaths were observed. The following grade 3 toxicities were observed: neutropenia (6 patients), thrombocytopenia (1 patient) and anemia (1 patient). The other toxicities observed, including gastrointestinal toxicity, were grade 2 or less. The median survival time of all patients was 526 days, and 1- and 2-year survival rates were 64.9% and 41.7%, respectively. Conclusion: TSLD is a potent regimen with a low toxicity profile for highly advanced gastric cancer.

Original languageEnglish
Pages (from-to)1631-1635
Number of pages5
JournalAnticancer Research
Volume26
Issue number2 B
Publication statusPublished - 2006 Mar

Fingerprint

Combination Drug Therapy
Cisplatin
Stomach Neoplasms
irinotecan
Therapeutics
Drug Therapy
Taxoids
Neutropenia
Informed Consent
Anemia
Neoplasms
Survival Rate
Survival

Keywords

  • Cisplatin
  • Combination chemotherapy
  • Gastric cancer
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Takahashi, T., Saikawa, Y., Yoshida, M., Kitagawa, Y., Otani, Y., Kubota, T., ... Kitajima, M. (2006). A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer. Anticancer Research, 26(2 B), 1631-1635.

A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer. / Takahashi, Tsunehiro; Saikawa, Yoshiro; Yoshida, Masashi; Kitagawa, Yuukou; Otani, Yoshihide; Kubota, Tetsuro; Kumai, Koichiro; Kitajima, Masaki.

In: Anticancer Research, Vol. 26, No. 2 B, 03.2006, p. 1631-1635.

Research output: Contribution to journalArticle

Takahashi, T, Saikawa, Y, Yoshida, M, Kitagawa, Y, Otani, Y, Kubota, T, Kumai, K & Kitajima, M 2006, 'A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer', Anticancer Research, vol. 26, no. 2 B, pp. 1631-1635.
Takahashi, Tsunehiro ; Saikawa, Yoshiro ; Yoshida, Masashi ; Kitagawa, Yuukou ; Otani, Yoshihide ; Kubota, Tetsuro ; Kumai, Koichiro ; Kitajima, Masaki. / A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer. In: Anticancer Research. 2006 ; Vol. 26, No. 2 B. pp. 1631-1635.
@article{7127bdfe5c9b47ccae0c369cdb632b41,
title = "A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer",
abstract = "Background: The surgical outcome for advanced gastric cancer, even following curative surgery, is associated with a poor prognosis. A pilot study in advanced gastric cancer patients was carried out using pre-operative chemotherapy with S-1 and low-dose cisplatin (CDDP) (TSLD). Patients and Methods: Twenty-one patients with stage IV gastric cancer were treated with TSLD as the initial treatment, after informed consent had been obtained. Surgery was performed when curative resection was deemed feasible in selected patients who showed improvement in their tumors. Other regimens including CPT-11 or taxanes were utilized as second-line chemotherapy when the tumor showed no change or progressive disease following TSLD therapy. Results: No patient had a complete response, while 11 had partial responses following TSLD therapy, yielding an overall response rate of 52.4{\%}. Fifteen out of 21 (71.4{\%}) underwent surgery following TSLD therapy, while curative surgery determined by histological investigation was performed in 10 out of 15 (47.6{\%}) patients. No grade 4 toxicities or treatment-related deaths were observed. The following grade 3 toxicities were observed: neutropenia (6 patients), thrombocytopenia (1 patient) and anemia (1 patient). The other toxicities observed, including gastrointestinal toxicity, were grade 2 or less. The median survival time of all patients was 526 days, and 1- and 2-year survival rates were 64.9{\%} and 41.7{\%}, respectively. Conclusion: TSLD is a potent regimen with a low toxicity profile for highly advanced gastric cancer.",
keywords = "Cisplatin, Combination chemotherapy, Gastric cancer, S-1",
author = "Tsunehiro Takahashi and Yoshiro Saikawa and Masashi Yoshida and Yuukou Kitagawa and Yoshihide Otani and Tetsuro Kubota and Koichiro Kumai and Masaki Kitajima",
year = "2006",
month = "3",
language = "English",
volume = "26",
pages = "1631--1635",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer

AU - Takahashi, Tsunehiro

AU - Saikawa, Yoshiro

AU - Yoshida, Masashi

AU - Kitagawa, Yuukou

AU - Otani, Yoshihide

AU - Kubota, Tetsuro

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2006/3

Y1 - 2006/3

N2 - Background: The surgical outcome for advanced gastric cancer, even following curative surgery, is associated with a poor prognosis. A pilot study in advanced gastric cancer patients was carried out using pre-operative chemotherapy with S-1 and low-dose cisplatin (CDDP) (TSLD). Patients and Methods: Twenty-one patients with stage IV gastric cancer were treated with TSLD as the initial treatment, after informed consent had been obtained. Surgery was performed when curative resection was deemed feasible in selected patients who showed improvement in their tumors. Other regimens including CPT-11 or taxanes were utilized as second-line chemotherapy when the tumor showed no change or progressive disease following TSLD therapy. Results: No patient had a complete response, while 11 had partial responses following TSLD therapy, yielding an overall response rate of 52.4%. Fifteen out of 21 (71.4%) underwent surgery following TSLD therapy, while curative surgery determined by histological investigation was performed in 10 out of 15 (47.6%) patients. No grade 4 toxicities or treatment-related deaths were observed. The following grade 3 toxicities were observed: neutropenia (6 patients), thrombocytopenia (1 patient) and anemia (1 patient). The other toxicities observed, including gastrointestinal toxicity, were grade 2 or less. The median survival time of all patients was 526 days, and 1- and 2-year survival rates were 64.9% and 41.7%, respectively. Conclusion: TSLD is a potent regimen with a low toxicity profile for highly advanced gastric cancer.

AB - Background: The surgical outcome for advanced gastric cancer, even following curative surgery, is associated with a poor prognosis. A pilot study in advanced gastric cancer patients was carried out using pre-operative chemotherapy with S-1 and low-dose cisplatin (CDDP) (TSLD). Patients and Methods: Twenty-one patients with stage IV gastric cancer were treated with TSLD as the initial treatment, after informed consent had been obtained. Surgery was performed when curative resection was deemed feasible in selected patients who showed improvement in their tumors. Other regimens including CPT-11 or taxanes were utilized as second-line chemotherapy when the tumor showed no change or progressive disease following TSLD therapy. Results: No patient had a complete response, while 11 had partial responses following TSLD therapy, yielding an overall response rate of 52.4%. Fifteen out of 21 (71.4%) underwent surgery following TSLD therapy, while curative surgery determined by histological investigation was performed in 10 out of 15 (47.6%) patients. No grade 4 toxicities or treatment-related deaths were observed. The following grade 3 toxicities were observed: neutropenia (6 patients), thrombocytopenia (1 patient) and anemia (1 patient). The other toxicities observed, including gastrointestinal toxicity, were grade 2 or less. The median survival time of all patients was 526 days, and 1- and 2-year survival rates were 64.9% and 41.7%, respectively. Conclusion: TSLD is a potent regimen with a low toxicity profile for highly advanced gastric cancer.

KW - Cisplatin

KW - Combination chemotherapy

KW - Gastric cancer

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=33645818388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645818388&partnerID=8YFLogxK

M3 - Article

C2 - 16619584

AN - SCOPUS:33645818388

VL - 26

SP - 1631

EP - 1635

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -